Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotinib and Gemcitabine in Advanced Pancreatic Cancer
NCT04131192Phase 1Terminated
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2019
- Primary completion
- Sep 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of larotinib in pancreatic cancer (PC), sponsored by Sunshine Lake Pharma. Primary endpoint: Rate of dose limiting toxicities at 21 days. Started Nov 2019; status: terminated.
02
Drugs
larotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04131192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04131192.